Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130732 | 0.90 | HRH3 (0.52) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL29557863 | 0.89 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL2202209 | 0.89 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL29520625 | 0.89 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL29516213 | 0.89 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL24620314 | 0.89 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL26922403 | 0.89 | HRH3 (0.51) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL10383112 | 0.87 | HRH3 (0.53) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL13713708 | 0.85 | MAOB (0.56) | HRH3MAOBMAOASLC6A4PDE4D | |
| SCHEMBL12938115 | 0.85 | HRH3 (0.46) | HRH3MAOBMAOASLC6A4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | ONECUREGEN CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | ONECUREGEN CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2019111225-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS | AVALIV THERAPEUTICS (US) | 2019-06-13 | — | — | WO | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | UNIV QUEENSLAND (AU) | 2015-02-05 | — | — | US | disclosed |
| US-8927503-B2 | Modulations of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-06 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080279821-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7166600-B2 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279821-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, SPINT2 | HRH3 3236/4885MAOB 1472/4885MAOA 1504/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | HRH3 2514/4885MAOB 2171/4885MAOA 2502/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | HRH3 1180/4885MAOB 334/4885MAOA 406/4885 |
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | AK2, CS, GOT2 | HRH3 4210/4885MAOB 4281/4885MAOA 3992/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | HRH3 896/4885MAOB 1538/4885MAOA 2947/4885 |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, DNPEP, CTSC | HRH3 3193/4885MAOB 1859/4885MAOA 2055/4885 |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | HRH3 404/4885MAOB 929/4885MAOA 1092/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | HRH3 13/4885MAOB 688/4885MAOA 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.